Ybrain
Latest round
- Series C
Last raised
- Jan 2020
Total raised
- $13M
Investors
- 7
About Ybrain
a. Ybrain develops electronic devices using micro-electrical stimulation technology for the treatment of various brain diseases, such as dementia and depression. Ybrain’s team of neuroscience, software, and hardware talents provide a wide range of product lines, including scan, doopang, stim, and pola. The scan is EEG diagnostic medical device while doopang is migraine treatment medical device. The stim is a food and drug administration licensed depression treatment medical device while pola is a mind and body stability, stress-relieving device. The company also provide mindd, a mental health care integration platform that offers scale inspection and smart management solution for sending and implementing scale inspections and their results.
Who invested in Ybrain
7 investors across 4 rounds
See all investors in Ybrain
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ybrain
Who invested in Ybrain?
Ybrain has 7 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ybrain raised?
Ybrain has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Ybrain last raise money?
Ybrain's most recent round on record is a Series C, in Jan 2020.
What does Ybrain do?
Ybrain is a medical devices & equipment company.
Where is Ybrain headquartered?
Ybrain is headquartered in Seoul, South Korea.
Which VCs invest in companies like Ybrain?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back medical devices & equipment companies at Ybrain's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series C
Raising like Ybrain? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.